SCYX
Price:
$0.669
Market Cap:
$28.07M
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Ha...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2014-05-02
Stock Exchange
NASDAQ
Ticker
SCYX
According to SCYNEXIS, Inc.’s latest financial reports and current stock price. The company's current ROE is -37.42%. This represents a change of 283.85% compared to the average of -9.75% of the last 4 quarters.
The mean historical ROE of SCYNEXIS, Inc. over the last ten years is -294.91%. The current -37.42% ROE has changed -87.31% with respect to the historical average. Over the past ten years (40 quarters), SCYX's ROE was at its highest in in the June 2023 quarter at 131.35%. The ROE was at its lowest in in the December 2022 quarter at -591.68%.
Average
-294.91%
Median
-82.89%
Minimum
-1942.75%
Maximum
91.88%
Discovering the peaks and valleys of SCYNEXIS, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.34%
Maximum Annual ROE = 91.88%
Minimum Annual Increase = -142.06%
Minimum Annual ROE = -1942.75%
| Year | ROE | Change |
|---|---|---|
| 2024 | -38.65% | -142.06% |
| 2023 | 91.88% | -104.73% |
| 2022 | -1942.75% | 2.34% |
| 2021 | -79.66% | -67.15% |
| 2020 | -242.49% | -41.78% |
| 2019 | -416.52% | 943.13% |
| 2018 | -39.93% | -65.89% |
| 2017 | -117.05% | 35.90% |
| 2016 | -86.13% | 10.75% |
| 2015 | -77.77% | 514.05% |
The current ROE of SCYNEXIS, Inc. (SCYX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-629.84%
5-year avg
-442.33%
10-year avg
-294.91%
SCYNEXIS, Inc.’s ROE is greater than Talphera, Inc. (-151.40%), greater than Cosmos Health Inc. (-74.28%), greater than Cadrenal Therapeutics, Inc. Common Stock (-279.52%), greater than Exicure, Inc. (-110.40%), greater than Klotho Neurosciences, Inc. (-201.59%), greater than CollPlant Biotechnologies Ltd. (-102.03%), greater than Sonnet BioTherapeutics Holdings, Inc. (-4648.06%), greater than Nexalin Technology, Inc. (-207.47%), greater than NeurAxis, Inc. (-340.23%), less than NeuroSense Therapeutics Ltd. (2.72%),
| Company | ROE | Market cap |
|---|---|---|
| -151.40% | $25.85M | |
| -74.28% | $13.51M | |
| -279.52% | $23.04M | |
| -110.40% | $42.96M | |
| -201.59% | $25.82M | |
| -102.03% | $26.70M | |
| -4648.06% | $8.43M | |
| -207.47% | $17.96M | |
| -340.23% | $28.86M | |
| 2.72% | $29.60M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like SCYNEXIS, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like SCYNEXIS, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is SCYNEXIS, Inc.'s ROE?
How is the ROE calculated for SCYNEXIS, Inc. (SCYX)?
What is the highest ROE for SCYNEXIS, Inc. (SCYX)?
What is the 3-year average ROE for SCYNEXIS, Inc. (SCYX)?
What is the 5-year average ROE for SCYNEXIS, Inc. (SCYX)?
How does the current ROE for SCYNEXIS, Inc. (SCYX) compare to its historical average?